

December 1, 2011

Dainippon Sumitomo Pharma Co., Ltd.  
Yoshitomiyakuhin Corporation  
Mitsubishi Tanabe Pharma Corporation

**Dainippon Sumitomo Pharma and Yoshitomiyakuhin  
terminate co-promotion of antipsychotics, LONASEN<sup>®</sup> and LULLAN<sup>®</sup>**

Dainippon Sumitomo Pharma Co., Ltd. (DSP, Headquarters: Osaka, Japan; President: Masayo Tada) and Yoshitomiyakuhin Corporation (Headquarters: Osaka, Japan; President: Kuniyoshi Wada), a consolidated subsidiary of Mitsubishi Tanabe Pharma Corporation (Headquarters: Osaka, Japan; President: Michihiro Tsuchiya) announce that a co-promotion agreement between the two companies for DSP's atypical antipsychotics LONASEN<sup>®</sup> and LULLAN<sup>®</sup>, will expire as of March 31, 2012, due to the end of the contract period.

As of April 2012, DSP will continue to provide information on LONASEN<sup>®</sup> and LULLAN<sup>®</sup> solely.

DSP and Yoshitomiyakuhin Corporation each will strengthen activities providing information to the field of psychiatry, further contributing to treatment in this therapeutic area.

Contact:

Corporate Communications  
Dainippon Sumitomo Pharma  
TEL +81-6-6203-1407

Corporate Communications Department  
Mitsubishi Tanabe Pharma Corporation  
TEL +81-6-6205-5211